Biopharma M&A maintains strength even as large deals wane

May 15, 2026 01:56 PM EDT DealsPharma Are phar­ma megadeals dead? Small­er tar­gets take pri­or­i­ty amid hunt for block­busters Max Bayer Senior Reporter Bio­phar­ma’s deals land­scape could hard­ly be bet­ter, as large com­pa­nies take a mul­ti-pronged ap­proach to with­stand an avalanche of ma­jor patent ex­piries. But there’s one … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER